T2 Biosystems Plans Own Laboratory to Produce Lyme Disease Diagnostic Kits -- Share Down
T2 Biosystems (TTOO) shares were down nearly 6% in recent trading Monday as the company disclosed plans to build or buy its own laboratory to produce the T2Lyme diagnostic kit.
The company previously had plans to launch the product through a partnership.
T2Lyme is a direct-from-blood molecular diagnostic test for the early detection of Borrelia burgdorferi, the bacterium that causes Lyme disease in the US, according to T2 Biosystems.
Price: 2.78, Change: -0.17, Percent Change: -5.76
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。